FilingReader Intelligence
NATCO launches generic Bosentan tablets with US exclusivity
August 20, 2025 at 05:39 AM UTC•By FilingReader AI
NATCO Pharma Limited launched Bosentan tablets for oral suspension, a generic version of Tracleer, in the United States with first-to-file status granting 180-day exclusivity.
The pediatric pulmonary arterial hypertension treatment targets a market with estimated sales of $10m for the 12 months ending June 2025.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
BSE:NATCOPHARM•Bombay Stock Exchange
News Alerts
Get instant email alerts when Natco Pharma publishes news
Free account required • Unsubscribe anytime